EMERYVILLE, Calif.--(BUSINESS WIRE)--Amyris, Inc. (NASDAQ:AMRS) announced today that it has entered into an agreement with Givaudan (SIX:GIVN), the global leader in the fragrances and flavors industry, headquartered in Vernier, Switzerland. Under the agreement, Givaudan will develop a derivative of BiofeneTM to be used as a building block for one of the most important proprietary fragrance ingredients in Givaudan’s palette. Biofene is the chemical, farnesene, produced using Amyris’s bio-based technology and production platform.
